Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment
NCT05318937 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 6, 2022
- Completion date
- February 23, 2024
- Enrollment
- 86 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.